文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

撒哈拉以南非洲三代头孢耐药肠杆菌血流感染流行率与结局的系统综述

Prevalence and outcome of bloodstream infections due to third-generation cephalosporin-resistant Enterobacteriaceae in sub-Saharan Africa: a systematic review.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该系统综述检索PubMed与Scopus(1990年1月至2019年9月),纳入40篇报告撒哈拉以南非洲血流感染肠杆菌三代头孢敏感性检测的研究,其中7篇报告死亡率。大肠埃希菌三代头孢耐药中位流行率为18.4%,克雷伯菌属为54.4%,非伤寒沙门菌为1.9%;因异质性过大未能合并死亡估计。

要点

  • 撒哈拉以南非洲血流感染中克雷伯菌属三代头孢耐药中位流行率达54.4%,大肠埃希菌为18.4%。
  • 非伤寒沙门菌三代头孢耐药中位流行率较低,为1.9%。
  • 因研究异质性过大,未能合并估计三代头孢耐药血流感染的死亡率。

核心结论

  • 撒哈拉以南非洲血流感染肠杆菌中三代头孢耐药水平高,但耐药感染的死亡负担仍不清楚。

研究设计与样本

  • 系统综述,检索PubMed与Scopus 1990年1月至2019年9月的原始数据研究,共纳入40篇文章,其中7篇报告死亡率。
  • 3GC-R定义为对头孢曲松、头孢噻肟或头孢他啶的表型耐药。
  • 结局以各病原体三代头孢耐药的中位流行率报告。

主要发现

  • 大肠埃希菌三代头孢耐药中位流行率为18.4%(IQR 10.5至35.2),来自20项研究。
  • 克雷伯菌属三代头孢耐药中位流行率为54.4%(IQR 24.3至81.2),来自28项研究。
  • 非伤寒沙门菌三代头孢耐药为1.9%(IQR 0至6.1),来自12项研究。
  • 因异质性过大,未能进行死亡率的合并估计。

临床怎么用

  • 提示在撒哈拉以南非洲经验性使用头孢曲松治疗脓毒症时,需考虑当地大肠埃希菌与克雷伯菌属较高的三代头孢耐药水平。
  • 应加强实验室药敏监测与临床结局数据的连接,以评估耐药感染的死亡负担。

局限性

  • 三代头孢耐药血流感染的死亡负担仍未知,非洲耐药感染缺乏临床结局数据。
  • 各研究报告异质性大,无法合并死亡率估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of bacterial bloodstream infections (BSIs) in sub-Saharan Africa (sSA) is high and antimicrobial resistance is likely to increase mortality from these infections. Third-generation cephalosporin-resistant (3GC-R) Enterobacteriaceae are of particular concern, given the widespread reliance on ceftriaxone for management of sepsis in Africa. OBJECTIVES: Reviewing studies from sSA, we aimed to describe the prevalence of 3GC resistance in Escherichia coli, Klebsiella and Salmonella BSIs and the in-hospital mortality from 3GC-R BSIs. METHODS: We systematically reviewed studies reporting 3GC susceptibility testing of E. coli, Klebsiella and Salmonella BSI. We searched PubMed and Scopus from January 1990 to September 2019 for primary data reporting 3GC susceptibility testing of Enterobacteriaceae associated with BSI in sSA and studies reporting mortality from 3GC-R BSI. 3GC-R was defined as phenotypic resistance to ceftriaxone, cefotaxime or ceftazidime. Outcomes were reported as median prevalence of 3GC resistance for each pathogen. RESULTS: We identified 40 articles, including 7 reporting mortality. Median prevalence of 3GC resistance in E. coli was 18.4% (IQR 10.5 to 35.2) from 20 studies and in Klebsiella spp. was 54.4% (IQR 24.3 to 81.2) from 28 studies. Amongst non-typhoidal salmonellae, 3GC resistance was 1.9% (IQR 0 to 6.1) from 12 studies. A pooled mortality estimate was prohibited by heterogeneity. CONCLUSIONS: Levels of 3GC resistance amongst bloodstream Enterobacteriaceae in sSA are high, yet the mortality burden is unknown. The lack of clinical outcome data from drug-resistant infections in Africa represents a major knowledge gap and future work must link laboratory surveillance to clinical data.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lester R, Musicha P, van Ginneken N, et al. Prevalence and outcome of bloodstream infections due to third-generation cephalosporin-resistant Enterobacteriaceae in sub-Saharan Africa: a systematic review. J Antimicrob Chemother. 2020. PMID: 31742611. doi:10.1093/jac/dkz464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。